We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Immunohistochemistry Evaluated for Tissue-Invasive Cytomegalovirus in Gastrointestinal Mucosal Biopsies

By LabMedica International staff writers
Posted on 04 Mar 2022

Cytomegalovirus (CMV) immunohistochemistry (IHC) is the most widely used method to diagnose CMV infection/reactivation in tissues in a pathology laboratory. More...



Cytomegalovirus (CMV), an encapsulated double-stranded DNA β-herpesvirus, often causes asymptomatic or mild mononucleosis-like primary infection followed by latent infection or chronic infection. About 40% to 100% of the world's adult population is seropositive for CMV.

Gastrointestinal (GI) CMV disease can manifest during primary infection or reactivation of latent virus. Reactivation of CMV is frequently seen in adults, especially in patients with immunocompromised conditions such as human immunodeficiency virus (HIV) infection, recipients of solid organ and stem cell transplant, and those with disease treated by immunosuppressive medications.

A team of pathologists at the New York University Langone Health (New York, NY, USA) included in a study total of 1,479 mucosal biopsies from the GI system. Their aim was to improve the efficiency of CMV immunohistochemistry (IHC) testing by evaluating immunopositive staining trends of tissue-invasive CMV in the gastrointestinal system. Immunohistochemistry was performed with specific antibodies against CMV (DAKO, Santa Clara, CA, USA).

The investigators reported that the overall positivity rate of CMV IHC was 4.73% (70/1,479). The positivity rate from physician-requested and pathologist-initiated tests was significantly different (7.54% versus 3.83%). Cases with severe inflammation showed a higher positive CMV rate than those with mild inflammation (5.37% versus 2.6%). Cytomegalovirus positivity in biopsies from post-transplant patients, inflammatory bowel disease, human immunodeficiency virus (HIV)/common variable immunodeficiency (CVID), cancer, and others was 19.69%, 3.84%, 23.33%, 9.0%, and 2.84%, respectively.

The positivity rate among post-transplant, HIV/CVID, or cancer patients was significantly higher than in other populations. Cases tested with multiple tissue blocks generated a higher positivity rate than those with a single block (7.77% versus 3.23%). Testing three to four blocks per case almost tripled the positive CMV detection rate (9.04%). Interestingly, using five or more blocks did not further ameliorate the positive CMV detection rate.

The authors concluded that physician request, immunosuppression, multiple blocks, and severe inflammation were strongly related to positive CMV IHC detection rate. These findings might provide value in helping pathologists manage CMV IHC testing more efficiently. The study published in the March 2022 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
New York University Langone Health 
DAKO 


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.